Literature DB >> 20674825

Development of a daily diary for patients with chronic idiopathic urticaria.

Susan D Mathias1, Stephen C Dreskin, Allen Kaplan, Sarbjit S Saini, Sheldon Spector, Karin E Rosén.   

Abstract

BACKGROUND: Chronic idiopathic urticaria (CIU) is a disease characterized by itching and skin hives or wheals of unknown cause that vary in size and last for at least 6 weeks. The criterion standard for measuring disease activity is the urticaria activity score (UAS). However, content validity of the UAS has not been previously reported.
OBJECTIVES: To identify outcomes important to patients with CIU, create an urticaria patient daily diary based on the UAS and input from patients, and assess its content validity.
METHODS: A qualitative research study was conducted in 2 stages using one-on-one telephone interviews of patients with CIU. In stage 1, patients were asked to discuss the impact of CIU on aspects of their life and to evaluate the content of the UAS. On the basis of this information, a patient daily diary, including UAS items, was developed. In stage 2, patients were interviewed to determine whether the urticaria patient daily diary was comprehensive and easily understood.
RESULTS: Stage 1 interviews showed that CIU has an extensive impact on patients, from the primary symptoms of itching, hives, and angioedema to the broader aspects of sleep and health-related quality of life. Stage 2 interviews demonstrated the content validity of the urticaria patient daily diary and resulted in minor modifications to the diary. When the urticaria patient daily diary was administered in conjunction with the Dermatology Life Quality Index and Medical Outcomes Study Sleep Scale, patients considered the assessment to be comprehensive, although some recommendations were made to include more items on emotional issues and other aspects of angioedema.
CONCLUSIONS: The final urticaria patient daily diary is an easy-to-administer, comprehensive assessment of symptoms for CIU patients. Future research is needed to establish its additional psychometric properties. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20674825     DOI: 10.1016/j.anai.2010.06.011

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  15 in total

1.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria.

Authors:  Emuella M Flood; James L Zazzali; Jennifer Devlen
Journal:  Patient       Date:  2013       Impact factor: 3.883

4.  Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

Authors:  Sarbjit S Saini; Carsten Bindslev-Jensen; Marcus Maurer; Jean-Jacques Grob; Emel Bülbül Baskan; Mary S Bradley; Janice Canvin; Abdelkader Rahmaoui; Panayiotis Georgiou; Oral Alpan; Sheldon Spector; Karin Rosén
Journal:  J Invest Dermatol       Date:  2014-07-21       Impact factor: 8.551

5.  Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticaria patients: a prospective case-control study.

Authors:  Tadech Boonpiyathad; Panitan Pradubpongsa; Atik Sangasapaviriya
Journal:  Dermatoendocrinol       Date:  2014-07-16

6.  The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Authors:  M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2017-07-10       Impact factor: 13.146

7.  Sense of coherence as a protective factor in chronic urticaria.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Pietrzak; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

8.  EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria.

Authors:  Emma Hawe; Doreen McBride; Maria-Magdalena Balp; Haijun Tian; Anna Halliday; Donald E Stull
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

9.  Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling.

Authors:  Donald E Stull; Doreen McBride; Katherine Houghton; Andrew Y Finlay; Ari Gnanasakthy; Maria-Magdalena Balp
Journal:  Adv Ther       Date:  2016-01-30       Impact factor: 3.845

10.  Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies.

Authors:  Ana M Gimenéz-Arnau; Sheldon Spector; Evgeniya Antonova; Benjamin Trzaskoma; Karin Rosén; Theodore A Omachi; Donald Stull; Maria-Magdalena Balp; Thomas Murphy
Journal:  Clin Transl Allergy       Date:  2016-08-18       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.